Trial intelligence / Profile preview

URLC10, TTK, and KOC1 Peptide Vaccine in Refractory NSCLC

NCT00674258Phase 2

Key facts

Status: Unknown
Start: May 2008
Primary completion: Apr 2009
Countries: 1
Sponsor: The University of Tokyo
Modality: Peptide-based Cancer Vaccines

Drugs: URLC10
Conditions: non-small cell lung cancer (NSCLC)

Overview

Phase 2, open-label, single-arm trial of URLC10 in non-small cell lung cancer (NSCLC), sponsored by The University of Tokyo. Primary endpoints: Safety (toxicities as assessed by NCI CTCAE version 3) at 2 months and Efficacy (Feasibility as evaluated by RECIST) at 2 months. Status: unknown.

Design

1 arm

Study design: Non-randomizedOpen-label

Experimental Arm
URLC10, TTK and KOC1 peptide vaccine

Who it enrols

Patients with advanced or recurrent non-small cell lung cancer who have failed at least one prior line of therapy and are HLA-A*2402 positive.

Endpoints

Primary

Safety (toxicities as assessed by NCI CTCAE version 3)2 months
Efficacy (Feasibility as evaluated by RECIST)2 months

Secondary

Immunological Responses2 months

Beyond the preview

Go deeper on NCT00674258.

Full results, competitive context and analysis are in the Gosset platform.

Full results & analysis

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT00674258.